CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IRIS International, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IRIS International, Inc.
9172 Eton Avenue
Phone: (818) 527-7000p:818 527-7000 Chatsworth, CA  91311  United States Ticker: IRISIRIS

This company was Merged or Acquired on 10/31/2012.
This company ceased filing statements with the SEC on 11/13/2012.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
IRIS International, Inc. is a manufacturer of automated in vitro diagnostic systems (IVD), sample processing products and personalized diagnostics tests for use in hospitals and laboratories worldwide. The Company’s IVD products analyze the chemistry and morphology of cells and sediments in a variety of body fluids. It is also a provider of automated urine microscopy systems, with more than 3,600 iQ microscopy analyzers shipped to date in over 50 countries. It is focused on developing, manufacturing and commercializing in vitro diagnostics instruments and consumables for urinalysis, including its flagship iQ analyzers, a family of fully-automated, image-based bench-top analyzers for urine microscopy. Its commercialized products and product pipeline comprise three main categories: morphology, sample processing and personalized medicine.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201212/31/2011YesYes-YesYes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer Cesar M.Garcia 59 11/20/2007 1/1/2002
Chief Financial Officer, Corporate Vice President - Finance Amin I.Khalifa 58 11/1/2010 10/11/2010
Corporate Vice President - Operations John U.Yi 51 10/1/2005 9/1/2003
10 additional Officers and Directors records available in full report.

Business Names
Business Name
AlliedPath, Inc.
Arista Molecular, Inc.
IRIS
8 additional Business Names available in full report.

General Information
Number of Employees: 387 (As of 3/1/2012)
Outstanding Shares: 18,007,300 (As of 5/4/2012)
Shareholders: 1,650
Stock Exchange: NASD
Federal Tax Id: 942579751
Fax Number: (818) 700-9661
Email Address: irisinc@proiris.com


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 5, 2021